Nanjing Pharmaceutical
Nanjing Pharmaceutical, also known as Nanjing Pharmaceutical Company Limited, is a prominent player in the pharmaceutical industry, headquartered in Nanjing, China. Established in 1995, the company has made significant strides in the development and manufacturing of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs) and finished dosage forms. With a strong operational presence across Asia and expanding into international markets, Nanjing Pharmaceutical is recognised for its commitment to quality and innovation. The company’s core offerings include generic medications and specialty pharmaceuticals, distinguished by their rigorous adherence to international standards and advanced production techniques. Nanjing Pharmaceutical has achieved notable milestones, positioning itself as a trusted name in the industry, with a focus on enhancing healthcare solutions globally. Its dedication to research and development continues to drive its success in a competitive market.
DitchCarbon Score
How does Nanjing Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nanjing Pharmaceutical's score of 19 is lower than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Nanjing Pharmaceutical's reported carbon emissions
In 2023, Nanjing Pharmaceutical, headquartered in China (CN), reported emissions data that does not specify absolute carbon emissions figures in kg CO2e. The company has not disclosed any Scope 1, 2, or 3 emissions data for the years 2021 to 2023. However, it has provided exhaust emissions intensity figures, with 2022 showing approximately 0.089574 kg CO2e per unit of revenue and 2021 at about 0.076237 kg CO2e per unit of revenue. Despite the lack of specific emissions data, Nanjing Pharmaceutical has not set any publicly available reduction targets or climate pledges. The absence of significant climate commitments or initiatives indicates a potential area for improvement in their sustainability strategy. The emissions data and performance metrics are sourced directly from NanJing Pharmaceutical Company Limited, with no cascaded data from a parent or related organization. As the company continues to operate in a climate-conscious market, establishing clear reduction targets and enhancing transparency in emissions reporting could bolster its environmental credibility.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nanjing Pharmaceutical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
